This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,071 subscribers getting it for FREE!
Big Earnings Week Ahead
What a week it will be for earnings, with Apple ($AAPL), Facebook ($FB), and Tesla ($TSLA) being three of the most prominent names to come. While exciting companies like Exact Sciences ($EXAS), Mastercard ($MA), Under Armour ($UAA), Qualcomm ($QCOM), Alibaba ($BABA), and Starbucks ($SBUX). Below is a calendar with the dates and expectations.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Subscribe
[poll id=”8″]
Exact Sciences
Subscribe to the MCM Stock Market Commentary to get it weekly and join the 3,071 subscribers getting it for FREE!
Exact Sciences is not a name most investors are familiar with but should get to know. Its stock is up nearly 285 percent in 2017, yes you read that right. The S&P 500, by comparison, is up only 15.25 percent. The meteoric rise in Exact Science has been fueled by its lead product Cologuard, a noninvasive test for the detection of Colon Cancer. Wall Street is looking for the company to show revenue grew by 131 percent since last year to $65.03 million while looking a net loss of $0.30. The company boast a $6 billion valuation and is expected to see revenue grow to $566 million by the year 2019. The company has been able to easily beat revenue estimates for each of the last two quarters.
EXAS Quarterly Actual Revenue data by YChartsa
[poll id=”9″]
Apple
Apple is the most critical company to report this week, and everyone will be watching to see not only what results are, but more importantly the guidance for next quarter, the year, and the launch of the new iPhone’s. Expectations are for revenue of $50.76 billion, and EPS of $1.87, while for the fiscal first quarter analysts are looking for revenue of $85.73 billion on EPS of $3.79. So regardless of how Apple reports this past quarter results, the market will likely only care about guidance for the fiscal first quarter, and of course iPhone shipments and demand. It is an outcome that will ripple throughout the iPhone supply chain.
Premium Content:
What Good Are The Analyst Worth!
Tech, Biotech, And Why BofA Can Go To $40
Tesla
Tesla reports this week as well, with expectations for revenue of $2.92 billion, and a net loss of $2.27. It will be all about Capex and cash burn, and of course the Model 3 launch. Any color around the “production hell” and perhaps more critical any updates to that 5,000 cars per week by December target. I can tell you I saw a Model 3 just yesterday at the Americana Mall in Manhasset. It is a very sleek looking car, although it is much smaller than I had imagined., which is perhaps why Tesla can get so much range on the car, despite the battery size. Additionally, it was discretely parked between two Model X SUV’s. It had no marking of the Model 3 on the trunk, which I found interesting.
Model 3 Pictures – Tesla Store Americana Mall, Long Island NY
Whatever the case it sure was cool to see the real thing.
The other companies will be sure essential to watch as well. Hope this helps get your week going.
Free Articles From Mike:
Celgene and Biogen May Be Signalling A Biotech Bottom
AMD Could Rise 10% Despite Results, Trades Indicate
Why Tesla’s Stock Is Breaking Down
Why Is McDonald’s Valued Like a Big Tech Stock?
Why Biogen May Sink Biotech Sector As Earnings Beat
Netflix Stock Likely to Rise as EPS Estimates Jump
Bank of America Could Rise Nearly 50%: Technical Analysis
AMD Could Break Out After Results
Qualcomm’s Bid For NXP Still Lacks Investor Support
Celgene’s Sharp Sell-Off Is Likely Overdone
Procter & Gamble Continues To Have Two Big Problems
GE: Getting Excited For The Future
Why IBM’s Big Stock Rally Won’t Last
Allergan Shares On The Verge Of Further Breakdown
We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.
-OR-
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]
clients of Mott Capital own shares of TSLA, MA, SBUX
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
Comments are closed.